4D Molecular Therapeutics Inc (NASDAQ: FDMT) on Friday, soared 6.10% from the previous trading day, before settling in for the closing price of $10.99. Within the past 52 weeks, FDMT’s price has moved between $2.23 and $12.34.
During the last 5-year period, the sales drop of Healthcare Sector giant was -9.89%. The company achieved an average annual earnings per share of -9.35%. With a float of $50.88 million, this company’s outstanding shares have now reached $57.14 million.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of 4D Molecular Therapeutics Inc is 10.95%, while institutional ownership is 65.79%. The most recent insider transaction that took place on Nov 17 ’25, was worth 17,315. In this transaction Chief Legal Officer of this company sold 1,635 shares at a rate of $10.59, taking the stock ownership to the 3,594 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 1,635 for $10.79, making the entire transaction worth $17,642.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.9 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.84) by -0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.93 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.65% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
4D Molecular Therapeutics Inc (FDMT) is currently performing well based on its current performance indicators. A quick ratio of 8.42 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5551.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.94, a number that is poised to hit -0.53 in the next quarter and is forecasted to reach -3.48 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Looking closely at 4D Molecular Therapeutics Inc (NASDAQ: FDMT), its last 5-days average volume was 0.64 million, which is a drop from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 75.34%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 91.74%, which indicates a significant increase from 89.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.86 in the past 14 days, which was higher than the 0.63 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.02, while its 200-day Moving Average is $5.86. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $12.08. Second resistance stands at $12.49. The third major resistance level sits at $13.10. If the price goes on to break the first support level at $11.06, it is likely to go to the next support level at $10.45. Now, if the price goes above the second support level, the third support stands at $10.03.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
Market capitalization of the company is 666.19 million based on 57,135K outstanding shares. Right now, sales total 40 K and income totals -160,870 K. The company made 90 K in profit during its latest quarter, and -56,880 K in sales during its previous quarter.
